Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Vancomycin Prophylaxis for Recurrent CDI
NCT03462459Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2018
- Primary completion
- Jul 2023
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Clostridioides difficile infection (CDI) comparing Vancomycin with Placebo (2 arms). Primary endpoint: Recurrent Clostridium Difficile Infection at 8 weeks. Started May 2018; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03462459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462459.